Your Health, We Care
Cibinqo is indicated for the treatment of adults and pediatric patients 12 years of age and older with refractory, moderate-to-severe atopic dermatitis whose disease is not adequately controlled with other systemic drug products, including biologics, or when use of those therapies is inadvisable.
Limitations of Use Cibinqo is not recommended for use in combination with other JAK inhibitors, biologic immunomodulators, or other immunosuppressants.
from FDA，2023.12
This article discusses the applicable population and clinical use of abuxitinib.What are the suitable populations for abuxitinib?Knowing who the drug is suitable for can help make ···【more】
Article source：Lucius LaosRelease date：2025-05-19Recommended：95
The medical community's exploration of new targeted drugs continues to drive the innovation of treatment options.What diseases is abuxitinib suitable for?Long-term skin problem···【more】
Article source：Lucius LaosRelease date：2025-05-16Recommended：94
A new class of oral drugs is changing the treatment landscape for specific inflammatory skin diseases.What are the indications for abuxitinibThe drug works by precisely modulating ···【more】
Article source：Lucius LaosRelease date：2025-05-16Recommended：629
Lucius Pharmaceuticals (Lao) LTD. (Lucius Pharmaceuticals), with its manufacturing campus in Laos located in the capital city of Vientiane in 2020, officially begins its great journey to make effective and affordable medicines available to people in need around the world...More
Lucius Pharmaceutical Co., Ltd., was established in 2020 in Vientiane, the capital of Laos. It aims to offer safe, effective, and affordable medicines globally. With a factory spanning 25,000 square meters, the company manufactures 200+ generic drugs in diverse therapeutic fields.
Address:No.26 Thongmang village, Xaythany district, Vientiane Capital, Laos
E-mail:laoslucius@gmail.com
Whatsapp:
